Resumo

BEZERUSKA, Cícero et al. Osteonecrosis of the jaw related to use of bisphosphonates. Rev. cir. traumatol. buco-maxilo-fac. [online]. 2012, vol.12, n.1, pp. 109-114. ISSN 1808-5210.

The bisphosphonates (BFs) are synthetic drugs used to treat multiple myeloma, bone pathologies associated with malignancy, Paget's disease and osteoporosis. The drug reduces bone resorption and inhibits the recruitment of osteoclasts. These drugs have a number of side effects, and a new complication known as biphosphonate-associated osteonecrosis (BaO) was recently identified. Objective: To review the literature on the subject, taking into account the etiological factors, mechanisms of action of these medications, their side effects and treatments. Methodology: We used all the records of patients diagnosed with osteonecrosis of the jaw at uFPR and Hospital XV from 2006. Results: The records showed a prevalence in females (58%). ages ranged from 55 to 81 years. The base disease with the greatest incidence was osteoporosis (35.7%). There was also a prevalence of patients using intravenously administered BFs. zoledronic acid was the most commonly used medication. The mandible was the most affected bone and the most widely used treatment was antibiotics and mouthwash with 0.12% chlorhexidine. Conclusion: The chronic use of BFs can lead to BAO. Given the difficulty of treatment, the dental surgeon plays a key role in prevention.

Palavras-chave : Bisphosphonates; Osteonecrosis; Osteoporosis.